Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharma/NIH)	Year complete	Primary publication	Full study treatment protocol
[Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison]	n = 776	Hoffman LaRoche	2024	Galeone C, Turati F, Nicolò M, et al. Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison. Drug Target Insights. 2024;18(1):105-111.	Individual patient-level data from the phase III clinical trials TENAYA and LUCERNE (faricimab cohort) and the real-world study RADIANCE (RADIANCE cohort) were used. An indirect comparison of the efficacy at 1 year of faricimab in two phase III clinical trials and the corresponding effectiveness of anti-VEGF in a real-world study was performed on patients with nAMD matched through propensity score weighting.